Abstract:Background: The advent of immune checkpoint inhibitors (ICIs) has revolutionized the therapeutic options of hepatobiliary malignancies. However, the clinical benefit provided by immunotherapy seems limited to a small subgroup of patients with hepatobiliary malignancies. The identification of reliable predictors of the response to immunotherapy is urgently needed. Data sources: Literature search was conducted in PubMed for relevant articles published up to May 2022. Information of clinical trials was obtained from https://clinicaltrials.gov/. Results: Biomarkers for ICI response of hepatobiliary malignancies remain in the exploration stage and lack compelling evidence. Tumor programmed death-ligand 1 (PD-L1) expression is the most widely studied biomarker in hepatocellular carcinoma (HCC) and biliary tract cancers (BTCs), but there are conflicting results on its predictive potential. Tumor mutational burden (TMB) is generally low both in HCC and BTCs, and the clinical trials of TMB are rare in hepatobiliary malignancies. Promisingly, mismatch repair deficiency (dMMR)/high microsatellite instability (MSI-H) may be a predictive biomarker of response to anti-PD-1 therapy in BTCs. Furthermore, some emerging biomarkers, such as gut microbiota, show predictive potential in the preliminary studies. Radiomics and liquid-biopsy biomarkers, including circulating tumor cells, circulating tumor DNA (ctDNA) and exosomal PD-L1 provide a quick and non-invasive approach for monitoring the ICI response, showing a new promising direction. Conclusions: Multiple potential biomarkers for predicting ICI response of hepatobiliary malignancies have been explored and tried to apply in clinic. Yet there is no robust evidence to prove their clinical value in predicting immunotherapeutic response for patients with hepatobiliary malignancies. The identification of predictors for response to ICIs is an urgent need and major challenge. Further studies are warranted to validate the role of emerging biomarkers in predicting immunotherapeutic responses.

Advances and prospects of biomarkers for immune checkpoint inhibitors

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors

Immune checkpoint inhibitors: recent progress and potential biomarkers

Progresses in biomarkers for cancer immunotherapy

Predictive Biomarkers for Cancer Immunotherapy with Immune Checkpoint Inhibitors

Predictive Biomarkers for Tumor Immune Checkpoint Blockade

Biomarkers for response to immunotherapy in hepatobiliary malignancies

Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1

Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1

Biomarkers for immune checkpoint inhibitors in colorectal cancer: recent advances and future perspectives

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients

Predictive biomarkers for checkpoint blockade-based immunotherapy

Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours

Tumor Immune Checkpoints and Their Associated Inhibitors

Predictive markers of immune checkpoint inhibitors

Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges

Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade